Company / EPS (Diluted)
Larimar Therapeutics, Inc. EPS (Diluted) History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.90
FY2019
5-year range
-$19.53 / -$1.90
FY2015-FY2019
Trend
+10.4%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has increased for 5 consecutive years, from $-19.65 in FY2014 to $-1.90 in FY2019.
Based on SEC 10-K filings.
-1.90 in FY2019.
Improved from $-2.78 to $-1.90 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Larimar Therapeutics, Inc.'s eps (diluted) has grown for 5 consecutive years.
- In FY2019, eps (diluted) increased 10.4% year-over-year.
- Lowest eps (diluted) in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2019 | -$1.90 | +10.4% |
| FY2018 | -$2.12 | +23.7% |
| FY2017 | -$2.78 | +7.3% |
| FY2016 | -$3.00 | +84.6% |
| FY2015 | -$19.53 | +0.6% |
| FY2014 | -$19.65 | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026